Clovis: FDA approves FoundationOne Liquid CDx to serve as Rubraca companion diagnostic to identify eligible patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer

Clovis: FDA approves FoundationOne Liquid CDx to serve as Rubraca companion diagnostic to identify eligible patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration approved the FoundationOne ® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test... Read More

Friday August 28, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology: First patient enrolled in Phase 2  of LIO-1 trial evaluating pairing Lucitanib, Opdivo

Clovis Oncology: First patient enrolled in Phase 2  of LIO-1 trial evaluating pairing Lucitanib, Opdivo

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’... Read More

Wednesday August 5, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy

Clovis Oncology to highlight Rubraca and Lucitanib non-clinical data at AACR virtual annual meeting June 22-24

Clovis Oncology to highlight Rubraca and Lucitanib non-clinical data at AACR virtual annual meeting June 22-24

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand... Read More

Wednesday June 17, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca, Lucitanib

Clovis Oncology announces completion of target enrollment in Phase 3 ATHENA trial

Clovis Oncology announces completion of target enrollment in Phase 3 ATHENA trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca ... Read More

Thursday June 11, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer

Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS), today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to... Read More

Friday May 29, 2020 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy

Clovis: Rubraca approved in U.S. for treatment of BRCA1/2-Mutant, metastatic castration-resistant prostate cancer

Clovis: Rubraca approved in U.S. for treatment of BRCA1/2-Mutant, metastatic castration-resistant prostate cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca ® (rucaparib) tablets for the treatment of adult patients with a... Read More

Monday May 18, 2020 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology: Rubraca ovarian cancer drug now available in Spain

Clovis Oncology: Rubraca ovarian cancer drug now available in Spain

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of... Read More

Monday March 2, 2020 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick Mahaffy

Clovis Oncology announces Rubraca cancer drug available in France

Clovis Oncology announces Rubraca cancer drug available in France

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in France. Rubraca is an option for monotherapy maintenance treatment... Read More

Monday February 3, 2020 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy